Tag - PALI

Feature

Palisade Bio guarding against post-operative disruption of GI function

Palisade Bio (NASDAQ:PALI) is advancing therapies that help patients with acute and chronic GI complications, stemming from post-operative tissue damage, to speed recovery and reduce hospital stays.

February 22, 2022

Developments

Palisade Bio to receive U.S. patent to treat adhesions and postoperative ileus

The United States Patent and Trademark Office (USPTO) has granted a new U.S. patent for Palisade Bio’s (NASDAQ:PALI) lead investigational drug product, LB1148, for use in treating adhesions and postoperative ileus...

December 8, 2021

Developments

Palisade Bio to receive European patent for LB1148

Palisade Bio (NASDAQ:PALI) was advised by the European Patent Office that it will receive a patent for its lead investigational drug product, LB1148. The patent will publish on Dec. 22, 2021, and provide protection...

November 30, 2021

Markets

Maxim starts Palisade Bio at buy; PT $7

Maxim Group initiated coverage of Palisade Bio (NASDAQ:PALI) with a “buy” rating and price target of $7. The stock closed at $2.73 on Aug. 30. Palisade Bio is a clinical-stage company developing LB1148, an oral...

August 31, 2021

Tag - PALI

Palisade Bio guarding against post-operative disruption of GI function

Palisade Bio to receive U.S. patent to treat adhesions and postoperative ileus

Palisade Bio to receive European patent for LB1148

Maxim starts Palisade Bio at buy; PT $7

General

More